Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial.

Name: Kaimen Rigor review — Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial.
Item: Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial.
Rating: 100
Author: Alpha1

Gaudet D, Gonciarz M, Shen X, Leohr JK, Beyer TP, Day JW, Mullins GR, Zhen EY, Hartley M, Larouche M, Konrad RJ, Benichou O, Ruotolo G

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.5★ (Weak), 0 critical, 2 high issues for “Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial.

Gaudet D, Gonciarz M, Shen X, Leohr JK, Beyer TP, Day JW, Mullins GR, Zhen EY, Hartley M, Larouche M, Konrad RJ, Benichou O, Ruotolo G

Read full text (PMC)

DOI

10.1038/s41591-025-03830-4

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/8059716f-da6c-41df-a776-d0b42b31bb89" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/8059716f-da6c-41df-a776-d0b42b31bb89/badge" alt="Kaimen Rigor review — 2.5★ (Weak), 0 critical, 2 high issues for “Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

02d0a5aea6fb6d4add25d1388d4f4ffcc54a5f859583f0517f3d59a37c136892

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial.

Gaudet D, Gonciarz M, Shen X, Leohr JK, Beyer TP, Day JW, Mullins GR, Zhen EY, Hartley M, Larouche M, Konrad RJ, Benichou O, Ruotolo G

Paper source

Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The efficacy claim is based on changes in lipid biomarkers (triglycerides, remnant cholesterol, LDL-C, non-HDL-C, ApoB, HDL-C) as surrogates for cardiovascular risk reduction. Although target engagement is demonstrated by increased ANGPTL3/8 levels, the paper does not cite validated evidence linking these specific lipid changes to clinical outcomes in this context, and the authors explicitly state that effects on cardiovascular risk remain to be established.
“LY3475766 thus significantly reduced atherogenic lipoprotein levels while increasing HDL-C levels; however, the effects on cardiovascular risk remain to be established.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported reductions in lipid biomarkers (e.g., triglycerides -70%, remnant cholesterol -86%, LDL-C -32%) are large relative to baseline, but the paper does not anchor these changes to established minimal clinically important differences or demonstrate that they translate to clinical benefit. The authors note that effects on cardiovascular risk remain to be established, indicating the effect size is not anchored to clinical meaningfulness.
“LY3475766 thus significantly reduced atherogenic lipoprotein levels while increasing HDL-C levels; however, the effects on cardiovascular risk remain to be established.”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit15 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 1 clinical trial with strong scientific premise, rigorous design, and transparent reporting. The main weaknesses are minor reporting gaps: randomization method not specified, exact p-values not consistently reported, and a few internal inconsistencies in reported effect sizes between abstract and results.

Both reviewers agreed on study type (interventional) and all dimension statuses. Minor divergences on power analysis (not applicable vs not reported) and reporting guideline (not reported vs reported and adequate) were resolved in favor of the more contextually appropriate designation. The statistics verification component could only check a subset of tests (0 recomputed) due to limited reporting of test statistics with df; therefore, statistical correctness is not fully verified.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction thoroughly reviews the ANGPTL protein family, the role of ANGPTL3/8 in inhibiting LPL, and genetic evidence supporting ANGPTL3/8 as a therapeutic target. The rationale for developing LY3475766 is logically derived from this evidence, and the study objectives follow directly. Limitations of prior research are implicitly addressed by the design of the antibody to specifically target the ANGPTL3/8 complex, but the paper does not explicitly discuss limitations of prior studies in a dedicated section.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing extensive prior work on ANGPTL3/8 biology and lipid metabolism, and clearly links this to the study rationale.

Evidence

paraphrase[Introduction, paragraphs 1-4]

“Recent studies on how the ANGPTL protein family modulates LPL activity have identified the mechanisms by which LPL activity is controlled in a tissue-specific manner.”

“Collectively, these observations suggest that ANGPTL3/8 may be an attractive drug target.”

Introduction ¶4Find in source

absence[Introduction]

The paper does not explicitly discuss limitations of prior research.

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing extensive prior work on ANGPTL3/8 biology and lipid metabolism, and clearly links this to the study rationale.

Evidence

paraphrase[Introduction, paragraphs 1-4]

“In recent years, agents inhibiting angiopoietin-like protein 3 (ANGPTL3) have been developed and have been shown to be effective in a wide spectrum of lipid disorders...”

“Collectively, these observations suggest that ANGPTL3/8 may be an attractive drug target.”

Introduction ¶4Find in source

paraphrase[Introduction, paragraph 5]

“In the current study, we describe a single ascending dose trial conducted with LY3475766 to assess its safety, tolerability, pharmacokinetics and pharmacodynamics in participants with mixed hyperlipidemia.”

The trial is described as randomized, double-blind, and placebo-controlled with a 6:2 allocation. Randomization method is not explicitly detailed but is standard for such trials. Blinding is stated. Power analysis is not reported, which is typical for phase 1 dose-escalation studies. Inclusion/exclusion criteria are clearly defined. Outlier handling is described in the statistical analysis. Controls are the placebo group. Independent replication is not applicable for a single trial.

Sub-criteria

controlsADEQUATE

power analysisNOT REPORTED

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The study design is rigorous for a phase 1 trial, with clear randomization, blinding, and a pre-specified analysis population, though some elements like power analysis are not applicable for a first-in-human dose-escalation study.

Evidence

paraphrase[Methods, Trial design and oversight]

“Participants were randomized to include six LY3475766 participants and two placebo (0.9% sodium chloride) participants in each cohort.”

“We conducted a phase 1, multicenter, randomized, double-blind, single ascending dose, first-in-human study.”

MethodsFind in source

“Log-transformed values outside three standard deviations of the mean were considered outliers and excluded from the dataset.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The study design is rigorous for a phase 1 trial, with clear randomization, blinding, and pre-specified endpoints, though some details like power analysis are not applicable for a first-in-human dose-escalation study.

Evidence

“We conducted a phase 1, multicenter, randomized, double-blind, single ascending dose, first-in-human study.”

MethodsFind in source

paraphrase[Methods, Study participants]

“Eligible participants were overtly healthy male or female adults 18–65 years of age, with a body mass index ≥18.5 to <40 kg m−2, fasting triglyceride level 135–499 mg dl−1, and fasting LDL-C level ≥70 mg dl−1.”

“Log-transformed values outside three standard deviations of the mean were considered outliers and excluded from the dataset.”

Statistical analysisFind in source

Sex is reported for the overall population and per group in Table 1. Age, BMI, and health status (mixed hyperlipidemia) are reported. Since both sexes are enrolled, sex justification is not applicable. Demographics are adequately reported in Table 1, including age, sex, and BMI. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for a human trial, including sex, age, BMI, and baseline lipid levels, with demographics in Table 1.

Evidence

“Male sex (%) | 75 | 100 | 100 | 50 | 67 | 67”

Table 1Find in source

“Age (years) | 52 (20, 65) | 44 (25, 61) | 50 (31, 62) | 56 (30, 60) | 52 (33, 65) | 51 (31, 58)”

Table 1Find in source

paraphrase[Methods, Study participants]

PASSReviewer 2· 90% conf

Biological variables are well reported for a human trial, including sex, age, BMI, and baseline lipid levels.

Evidence

paraphrase[Results, Baseline characteristics]

“A total of 75% of the participants were male, with a median age of 49 years, body mass index of 30.4 kg m−2, triglycerides 194 mg dl−1 and LDL-C 143 mg dl−1.”

“Table 1 Baseline characteristics of healthy participants with dyslipidemia”

Table 1Find in source

The paper states that the trial was approved by the institutional review board or ethics committee at each site, and that participants provided written informed consent. It also states compliance with the Declaration of Helsinki and ICH-GCP. Although the specific IRB names are not given, the statement is adequate for a clinical trial report.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are adequately reported: the trial was approved by an IRB/ethics committee, participants gave written informed consent, and compliance with the Declaration of Helsinki and ICH-GCP is stated.

Evidence

“The trial was approved by the institutional review board or ethics committee at each site.”

MethodsFind in source

“Participants provided written informed consent.”

MethodsFind in source

“The trial was conducted in accordance with the Declaration of Helsinki, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guideline for Good Clinical Practice, and applicable laws and regulations.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals and consent are adequately reported.

Evidence

“The trial was approved by the institutional review board or ethics committee at each site.”

MethodsFind in source

“Participants provided written informed consent.”

MethodsFind in source

LY3475766 is described as a fully human monoclonal antibody, and its development is detailed. The placebo is identified as 0.9% sodium chloride. Statistical software (SAS 9.4) and PK software (Phoenix WinNonlin 8.1) are named. Other reagents are not applicable as this is a clinical trial without wet-lab assays.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product LY3475766 is adequately identified as a human monoclonal antibody, and the statistical software is identified; other bench resources are not applicable.

Evidence

paraphrase[Introduction, paragraph 4]

“we developed a fully human anti-ANGPTL3/8 antibody, LY3475766, that binds to the same ANGPTL3/8 active site epitope that is recognized by LPL and ApoA-V.”

“Data analysis was performed using SAS version 9.4.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (LY3475766) is adequately identified, and software tools are named.

Evidence

“LY3475766, a human monoclonal antibody that specifically blocks ANGPTL3/8-mediated inhibition of LPL activity.”

AbstractFind in source

“Data analysis was performed using SAS version 9.4.”

Statistical analysisFind in source

“Pharmacokinetics were determined using noncompartmental methods (Phoenix WinNonlin version 8.1)”

MethodsFind in source

The paper names the statistical tests used (mixed model for repeated measures, Pearson correlation, power model for dose proportionality). Assumptions are handled by log-transformation and outlier exclusion. Exact p-values are not always given, but effect sizes with confidence intervals are reported, which is acceptable for a clinical trial. Software is identified. Data presentation includes per-group n and standard errors. Mathematical plausibility checks were not possible for most outcomes due to continuous data and small n, but no obvious errors were found.

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Statistical methods are appropriate and adequately described, with named tests, effect sizes with CIs, and software identified; exact p-values are not always reported but this is acceptable for a phase 1 trial.

Evidence

“A mixed model for repeated measures was used to evaluate treatment effect for the parameter’s change from baseline in LDL-C, remnant cholesterol, triglyceride, ApoB and ANGPTL3/8 levels.”

Statistical analysisFind in source

paraphrase[Results, Pharmacokinetics and target engagement]

“The ratio of the dose-normalized geometric mean Cmax of 600 mg versus 100 mg LY3475766 was 6.9 (90% confidence interval: 2.9–16.3).”

paraphrase[Results, Lipid profile correlation analysis]

“Extended Data Tables – list Pearson correlation coefficients (r) and P values for correlations among changes of key measures”

PASSReviewer 2· 85% conf

Statistical methods are appropriate and adequately described, with effect sizes and confidence intervals reported.

Evidence

“A mixed model for repeated measures was used to evaluate treatment effect for the parameter’s change from baseline in LDL-C, remnant cholesterol, triglyceride, ApoB and ANGPTL3/8 levels.”

Statistical analysisFind in source

paraphrase[Results, Pharmacokinetics and target engagement]

“The ratio of the dose-normalized geometric mean Cmax of 600 mg versus 100 mg LY3475766 was 6.9 (90% confidence interval: 2.9–16.3).”

“Due to computational limitations in SAS, P values are presented in the table to only four decimal places.”

Statistical analysisFind in source

The data availability statement is detailed, specifying that individual participant data are available after anonymization through a managed access process via Vivli, with conditions and timeframe. This is adequate for a clinical trial. Source data for figures are provided as supplementary material. Code sharing is not applicable as no custom code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is adequately described with a concrete mechanism for accessing individual participant data via Vivli, and the paper provides source data for figures.

Evidence

“Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization, except for pharmacokinetic or genetic data. Data are available by request 6 months after the indication studied has been approved in the US and EU and after primary publication acceptance, whichever is later.”

Data availabilityFind in source

“Source Data Figs. 1–5 and Extended Data Figs. 2–5”

Supplementary materialFind in source

PASSReviewer 2· 95% conf

Data availability is well described with a concrete access route via Vivli, and source data are provided.

Evidence

Data availabilityFind in source

“Source Data Figs. 1–5 and Extended Data Figs. 2–5”

Supplementary materialFind in source

The trial is registered (NCT04052594). Methods are detailed enough for replication. A reporting summary is mentioned. All outcomes appear to be reported, including negative findings. Limitations are discussed in the Discussion. Conclusions are proportional to the evidence. Funding and competing interests are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The paper is transparent: methods are detailed, the trial is registered, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

“ClinicalTrials.gov registration: NCT04052594”

AbstractFind in source

“Further studies are needed to confirm these findings, with the next steps likely to include a multiple ascending dose study to determine the optimal dosing of LY3475766”

Discussion ¶8Find in source

“These results warrant further human trials to assess the safety and efficacy of LY3475766 for the treatment of lipid disorders and for the prevention and/or treatment of atherosclerotic CVD, acute pancreatitis, or other morbidities.”

DiscussionFind in source

PASSReviewer 2· 90% conf

Reporting is transparent with trial registration, detailed methods, and discussion of limitations.

Evidence

“ClinicalTrials.gov registration: NCT04052594”

AbstractFind in source

“Further information on research design is available in the linked to this article.”

AbstractFind in source

“This work was supported by Eli Lilly and Company.”

AcknowledgementsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 48 references by DOI: 1 verified — 47 no DOI (shown, not verified).

3 data/code links checked; 3 live.

Copyediting

15 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 15 minor suggestions below.

15 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported, with no major integrity concerns. An informed reader should weigh the minor internal inconsistencies in reported effect sizes (abstract vs results) and the lack of explicit randomization method details, which are typical for phase 1 trials but could warrant clarification. No erratum is required, but the authors may consider issuing a correction for the inconsistent numbers.

1.
HIGHcopyedit
Reconcile the maximum percent change values reported in the Abstract with those in the Results section and Figure 2 legend (e.g., triglycerides −69.9% vs −70.4%, remnant cholesterol −84.4% vs −85.7%, LDL-C −36.5% vs −31.9%, non-HDL-C −37.2% vs −34.9%, ApoB −31.4% vs −29.3%, HDL-C +21.2% vs +26.7%).
Internal inconsistencies in reported effect sizes undermine data integrity and could confuse readers; a correction is warranted.
2.
HIGHreporting
In the Methods, specify the randomization method (e.g., computer-generated random sequence, block size) and whether allocation was concealed.
Transparency of randomization is a key methodological detail expected in clinical trial reports.
3.
MEDIUMstatistics
In the Results, report exact p-values for all primary and secondary comparisons, or explicitly state that effect sizes with confidence intervals are the primary reporting method.
Exact p-values facilitate interpretation and meta-analysis; the current reporting is incomplete.
4.
MEDIUMreporting
In the Methods, mention adherence to a reporting guideline such as CONSORT and consider submitting a CONSORT checklist as supplementary material.
Explicit adherence to reporting guidelines improves transparency and reproducibility.
5.
MEDIUMreporting
In the Methods, clarify the blinding process (who was blinded, how allocation was concealed).
Detailed blinding procedures strengthen confidence in the trial's internal validity.
6.
MEDIUMstatistics
In the Methods, provide more detail on the outlier exclusion criteria and report how many participants were excluded.
Transparent outlier handling is essential for reproducibility and assessing robustness.
7.
MEDIUMreporting
In the Methods, clarify the power model description for dose proportionality (e.g., linear regression of log(Cmax) on log(dose)).
Clearer statistical descriptions aid reader understanding and replication.
8.
LOWcopyedit
Fix the typo 'ANPTL3/8' to 'ANGPTL3/8' in the Abstract.
Correcting typos improves professionalism and clarity.
9.
LOWreporting
In the Introduction, add a brief paragraph explicitly discussing limitations of prior ANGPTL3/8 studies and how the current study addresses them.
Explicitly addressing prior limitations strengthens the scientific premise.
10.
LOWdata code
In the Data Availability section, clarify that the source data for figures are available as supplementary files and provide a direct link or accession number if applicable.
Clearer data access instructions improve usability and transparency.

Full text (52,716 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial.

Gaudet D, Gonciarz M, Shen X, Leohr JK, Beyer TP, Day JW, Mullins GR, Zhen EY, Hartley M, Larouche M, Konrad RJ, Benichou O, Ruotolo G

Read full text (PMC)

DOI

10.1038/s41591-025-03830-4

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/8059716f-da6c-41df-a776-d0b42b31bb89" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/8059716f-da6c-41df-a776-d0b42b31bb89/badge" alt="Kaimen Rigor review — 2.5★ (Weak), 0 critical, 2 high issues for “Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

02d0a5aea6fb6d4add25d1388d4f4ffcc54a5f859583f0517f3d59a37c136892

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The efficacy claim is based on changes in lipid biomarkers (triglycerides, remnant cholesterol, LDL-C, non-HDL-C, ApoB, HDL-C) as surrogates for cardiovascular risk reduction. Although target engagement is demonstrated by increased ANGPTL3/8 levels, the paper does not cite validated evidence linking these specific lipid changes to clinical outcomes in this context, and the authors explicitly state that effects on cardiovascular risk remain to be established.
“LY3475766 thus significantly reduced atherogenic lipoprotein levels while increasing HDL-C levels; however, the effects on cardiovascular risk remain to be established.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported reductions in lipid biomarkers (e.g., triglycerides -70%, remnant cholesterol -86%, LDL-C -32%) are large relative to baseline, but the paper does not anchor these changes to established minimal clinically important differences or demonstrate that they translate to clinical benefit. The authors note that effects on cardiovascular risk remain to be established, indicating the effect size is not anchored to clinical meaningfulness.
“LY3475766 thus significantly reduced atherogenic lipoprotein levels while increasing HDL-C levels; however, the effects on cardiovascular risk remain to be established.”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit15 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Overstated conclusions

2 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing extensive prior work on ANGPTL3/8 biology and lipid metabolism, and clearly links this to the study rationale.

Evidence

paraphrase[Introduction, paragraphs 1-4]

“Recent studies on how the ANGPTL protein family modulates LPL activity have identified the mechanisms by which LPL activity is controlled in a tissue-specific manner.”

“Collectively, these observations suggest that ANGPTL3/8 may be an attractive drug target.”

Introduction ¶4Find in source

absence[Introduction]

The paper does not explicitly discuss limitations of prior research.

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing extensive prior work on ANGPTL3/8 biology and lipid metabolism, and clearly links this to the study rationale.

Evidence

paraphrase[Introduction, paragraphs 1-4]

“In recent years, agents inhibiting angiopoietin-like protein 3 (ANGPTL3) have been developed and have been shown to be effective in a wide spectrum of lipid disorders...”

“Collectively, these observations suggest that ANGPTL3/8 may be an attractive drug target.”

Introduction ¶4Find in source

paraphrase[Introduction, paragraph 5]

Sub-criteria

controlsADEQUATE

power analysisNOT REPORTED

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Evidence

paraphrase[Methods, Trial design and oversight]

“Participants were randomized to include six LY3475766 participants and two placebo (0.9% sodium chloride) participants in each cohort.”

“We conducted a phase 1, multicenter, randomized, double-blind, single ascending dose, first-in-human study.”

MethodsFind in source

“Log-transformed values outside three standard deviations of the mean were considered outliers and excluded from the dataset.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Evidence

“We conducted a phase 1, multicenter, randomized, double-blind, single ascending dose, first-in-human study.”

MethodsFind in source

paraphrase[Methods, Study participants]

“Log-transformed values outside three standard deviations of the mean were considered outliers and excluded from the dataset.”

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for a human trial, including sex, age, BMI, and baseline lipid levels, with demographics in Table 1.

Evidence

“Male sex (%) | 75 | 100 | 100 | 50 | 67 | 67”

Table 1Find in source

“Age (years) | 52 (20, 65) | 44 (25, 61) | 50 (31, 62) | 56 (30, 60) | 52 (33, 65) | 51 (31, 58)”

Table 1Find in source

paraphrase[Methods, Study participants]

PASSReviewer 2· 90% conf

Biological variables are well reported for a human trial, including sex, age, BMI, and baseline lipid levels.

Evidence

paraphrase[Results, Baseline characteristics]

“A total of 75% of the participants were male, with a median age of 49 years, body mass index of 30.4 kg m−2, triglycerides 194 mg dl−1 and LDL-C 143 mg dl−1.”

“Table 1 Baseline characteristics of healthy participants with dyslipidemia”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Evidence

“The trial was approved by the institutional review board or ethics committee at each site.”

MethodsFind in source

“Participants provided written informed consent.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals and consent are adequately reported.

Evidence

“The trial was approved by the institutional review board or ethics committee at each site.”

MethodsFind in source

“Participants provided written informed consent.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product LY3475766 is adequately identified as a human monoclonal antibody, and the statistical software is identified; other bench resources are not applicable.

Evidence

paraphrase[Introduction, paragraph 4]

“we developed a fully human anti-ANGPTL3/8 antibody, LY3475766, that binds to the same ANGPTL3/8 active site epitope that is recognized by LPL and ApoA-V.”

“Data analysis was performed using SAS version 9.4.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (LY3475766) is adequately identified, and software tools are named.

Evidence

“LY3475766, a human monoclonal antibody that specifically blocks ANGPTL3/8-mediated inhibition of LPL activity.”

AbstractFind in source

“Data analysis was performed using SAS version 9.4.”

Statistical analysisFind in source

“Pharmacokinetics were determined using noncompartmental methods (Phoenix WinNonlin version 8.1)”

MethodsFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesINADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Evidence

“A mixed model for repeated measures was used to evaluate treatment effect for the parameter’s change from baseline in LDL-C, remnant cholesterol, triglyceride, ApoB and ANGPTL3/8 levels.”

Statistical analysisFind in source

paraphrase[Results, Pharmacokinetics and target engagement]

“The ratio of the dose-normalized geometric mean Cmax of 600 mg versus 100 mg LY3475766 was 6.9 (90% confidence interval: 2.9–16.3).”

paraphrase[Results, Lipid profile correlation analysis]

“Extended Data Tables – list Pearson correlation coefficients (r) and P values for correlations among changes of key measures”

PASSReviewer 2· 85% conf

Statistical methods are appropriate and adequately described, with effect sizes and confidence intervals reported.

Evidence

“A mixed model for repeated measures was used to evaluate treatment effect for the parameter’s change from baseline in LDL-C, remnant cholesterol, triglyceride, ApoB and ANGPTL3/8 levels.”

Statistical analysisFind in source

paraphrase[Results, Pharmacokinetics and target engagement]

“The ratio of the dose-normalized geometric mean Cmax of 600 mg versus 100 mg LY3475766 was 6.9 (90% confidence interval: 2.9–16.3).”

“Due to computational limitations in SAS, P values are presented in the table to only four decimal places.”

Statistical analysisFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is adequately described with a concrete mechanism for accessing individual participant data via Vivli, and the paper provides source data for figures.

Evidence

Data availabilityFind in source

“Source Data Figs. 1–5 and Extended Data Figs. 2–5”

Supplementary materialFind in source

PASSReviewer 2· 95% conf

Data availability is well described with a concrete access route via Vivli, and source data are provided.

Evidence

Data availabilityFind in source

“Source Data Figs. 1–5 and Extended Data Figs. 2–5”

Supplementary materialFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The paper is transparent: methods are detailed, the trial is registered, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

“ClinicalTrials.gov registration: NCT04052594”

AbstractFind in source

“Further studies are needed to confirm these findings, with the next steps likely to include a multiple ascending dose study to determine the optimal dosing of LY3475766”

Discussion ¶8Find in source

DiscussionFind in source

PASSReviewer 2· 90% conf

Reporting is transparent with trial registration, detailed methods, and discussion of limitations.

Evidence

“ClinicalTrials.gov registration: NCT04052594”

AbstractFind in source

“Further information on research design is available in the linked to this article.”

AbstractFind in source

“This work was supported by Eli Lilly and Company.”

AcknowledgementsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 48 references by DOI: 1 verified — 47 no DOI (shown, not verified).

3 data/code links checked; 3 live.

Copyediting

15 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 15 minor suggestions below.

15 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHcopyedit
Reconcile the maximum percent change values reported in the Abstract with those in the Results section and Figure 2 legend (e.g., triglycerides −69.9% vs −70.4%, remnant cholesterol −84.4% vs −85.7%, LDL-C −36.5% vs −31.9%, non-HDL-C −37.2% vs −34.9%, ApoB −31.4% vs −29.3%, HDL-C +21.2% vs +26.7%).
Internal inconsistencies in reported effect sizes undermine data integrity and could confuse readers; a correction is warranted.
2.
HIGHreporting
In the Methods, specify the randomization method (e.g., computer-generated random sequence, block size) and whether allocation was concealed.
Transparency of randomization is a key methodological detail expected in clinical trial reports.
3.
MEDIUMstatistics
In the Results, report exact p-values for all primary and secondary comparisons, or explicitly state that effect sizes with confidence intervals are the primary reporting method.
Exact p-values facilitate interpretation and meta-analysis; the current reporting is incomplete.
4.
MEDIUMreporting
In the Methods, mention adherence to a reporting guideline such as CONSORT and consider submitting a CONSORT checklist as supplementary material.
Explicit adherence to reporting guidelines improves transparency and reproducibility.
5.
MEDIUMreporting
In the Methods, clarify the blinding process (who was blinded, how allocation was concealed).
Detailed blinding procedures strengthen confidence in the trial's internal validity.
6.
MEDIUMstatistics
In the Methods, provide more detail on the outlier exclusion criteria and report how many participants were excluded.
Transparent outlier handling is essential for reproducibility and assessing robustness.
7.
MEDIUMreporting
In the Methods, clarify the power model description for dose proportionality (e.g., linear regression of log(Cmax) on log(dose)).
Clearer statistical descriptions aid reader understanding and replication.
8.
LOWcopyedit
Fix the typo 'ANPTL3/8' to 'ANGPTL3/8' in the Abstract.
Correcting typos improves professionalism and clarity.
9.
LOWreporting
In the Introduction, add a brief paragraph explicitly discussing limitations of prior ANGPTL3/8 studies and how the current study addresses them.
Explicitly addressing prior limitations strengthens the scientific premise.
10.
LOWdata code
In the Data Availability section, clarify that the source data for figures are available as supplementary files and provide a direct link or accession number if applicable.
Clearer data access instructions improve usability and transparency.

Full text (52,716 chars)Analyzed: Aug 15, 2026